Miami Cancer Institute’s John Diaz, M.D., and Manmeet Ahluwalia, M.D., were featured at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting. Dr. Diaz presented research on a biomarker that can be used to identify patients with recurrent gynecologic cancer who might benefit from immunotherapy. The study is looking at improved response rates among those with FATSI negative tumors, and a phase II trial is investigating response in women with recurrent cervical cancer treated with a combination of immunotherapy and PARP inhibitors.
To view the abstract, “Immunotherapy in combination with PARP inhibition in advanced cervical cancer patients functionally competent or deficient for the Fanconi anemia repair pathway,” please visit ASCO’s Meeting Library.
Dr. Ahluwalia presented on a new tool that is helping predict the overall and disease-free survival for brain tumor patients. The abstract, “Superior overall survival (OS) and disease-free survival (DFS) predictions for patients with glioblastoma multiform (GBM) using Cellworks Singula: myCare-022-03,” can also be accessed on ASCO’s Meeting Library.